Data as of Oct 17
| 0.00 / 0.00%|
The 1 analysts offering 12-month price forecasts for Nymox Pharmaceutical Corp have a median target of 9.00, with a high estimate of 9.00 and a low estimate of 9.00. The median estimate represents a +73.08% increase from the last price of 5.20.
The current consensus among 1 polled investment analysts is to Buy stock in Nymox Pharmaceutical Corp. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.